NasdaqGS:NVAXBiotechs
Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates
Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to existing licensed vaccines. This positive news, coupled with the FDA's approval of Nuvaxovid for certain age groups and the subsequent $175 million milestone payment from Sanofi, likely fueled increased investor confidence. Meanwhile, broader market gains such as the S&P 500's upward trajectory and...